View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
January 27, 2021updated 12 Jul 2022 11:29am

Care Access Research and AstraZeneca partner for Covid-19 trial

Decentralised research organisation (DRO) Care Access Research has collaborated with AstraZeneca to speed up the Phase III STORM CHASER clinical trial in the US assessing the latter’s long-acting monoclonal antibody (LAAB) combination, AZD7442, for preventing Covid-19.

Decentralised research organisation (DRO) Care Access Research has collaborated with AstraZeneca to speed up the Phase III STORM CHASER clinical trial in the US assessing the latter’s long-acting monoclonal antibody (LAAB) combination, AZD7442, for preventing Covid-19.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Care Access is supporting the trial evaluating the safety and efficacy of AZD7442 for post-exposure prophylaxis and pre-emptive treatment in around 1,125 subjects in the US and the UK.

The organisation will provide decentralised, mobile research site operations for AstraZeneca’s trial in the US.

Adult participants who were exposed to SARS-COV-2 and are at the risk of developing Covid-19 will be part of the study.

The trial will have individuals living or working at long-term care facilities, industrial and military settings.

AstraZeneca Microbial Sciences BioPharmaceuticals R&D vice-president Mark Esser said: “We are excited to collaborate with Care Access and leverage their unique decentralised, mobile model for this important Phase III trial for AZD7442 in the US.

“AZD7442 has the potential to be an important preventative and therapeutic medicine against Covid-19.”

In a separate development, clinical-stage biotechnology company Vaxart has reported additional results from its SARS-CoV-2 Hamster Challenge Study on oral Covid-19 vaccine candidate.

The vaccine candidate is designed to express the SARS-CoV-2 S protein as well as the nucleocapsid (N) protein.

According to the latest histology data from the study, hamsters given two doses of the oral tablet vaccine showed a substantial reduction in lung inflammation versus those not receiving the vaccine.

Vaxart CEO Andrei Floroiu said: “Our oral vaccine could help fight the Covid-19 epidemic globally because it is stable at room temperature making it easier to transport, store, and administer than injectables. It may also appeal to those uncomfortable with injections.”

Last October, Vaxart started dosing participants in a Phase I clinical trial of oral tablet Covid-19 vaccine candidate, VXA-CoV2-1.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena